- The approval is based on a P-III study evaluating the safety, PK & efficacy of Trikafta in 66 children aged 6-11yrs. old with CF with either two copies of F508del mutations or one copy of F508del mutation & one minimal function mutation for 24wks.
- The company has filed the application in EMA & MHRA and plans to file for expanded use in Switzerland, Australia & Israel in 2021. Additionally, a new dosage strength of Trikafta is now available (elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 75 mg and ivacaftor 75 mg)
- Trikafta is an approved therapy for patients aged ≥12yrs. with CF with certain mutations in the US, Switzerland, Australia, Israel, EU & UK as Kaftrio + Kalydeco
Click here to read full press release/ article | Ref: Vertex | Image: Glassdoor